Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVax and Pembrolizumab Following Rituximab in Follicular Lymphoma
NCT03361852Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoVax in follicular lymphoma (FL) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Feasibility of Neovax following 4 weekly doses of rituximab at 2 years. Started Mar 2022; status: active, not recruiting.
02
Drugs
NeoVax
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03361852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361852.